Should You Buy Regentis Biomaterials Ltd. Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Regentis Biomaterials Ltd. (RGNT) presents a moderate quality profile with a QOC score of 4.3/10. Trading at $1.81, separating genuine undervalued opportunities from value traps is essential, as detailed by our model data.
The short answer: 0 of 1 CirclFi valuation models project upside for Regentis Biomaterials Ltd. (RGNT) at $1.81 — the model consensus leans bearish, with a Quality Score of 4.3/10 and Value-Trap risk of 36/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
What Is the Investment Case for Regentis Biomaterials Ltd. (RGNT) in 2026?
What Is the Bull Case vs the Bear Case for Regentis Biomaterials Ltd. (RGNT)?
| Bull case | Bear case — $1.27 target (-29.6%) |
|---|---|
| No active model projects meaningful upside for RGNT at $1.81. Bulls would have to argue that qualitative factors the models cannot measure will unlock value. | According to the CirclFi Quality of Company (QOC) framework, Regentis Biomaterials Ltd.'s rating of 4.3/10 indicates below-average quality, raising questions about sustainable earnings levels. |
| According to the CirclFi Deep Alpha Valuation Engine, the Dynamic NAV model sees the stock as overvalued with a fair value of $1.27 (-29.6%), suggesting that the market price embeds overly optimistic growth assumptions. |
How Does RGNT Compare to Its Medical Instruments & Supplies Peers?
Valuation data pages: YBGJ · UEEC · DXR · TUTH · PLSE · ZJYL · NEPH · SOLV · RVP · ISRG · RMD
Which Other Stocks Score Like RGNT on Quality?
Closest companies to RGNT’s Quality of Company score of 4.3/10, across all industries.
- NVNO — enVVeno Medical Corporation (QOC 4.3) · analysis
- BBLG — Bone Biologics Corporation (QOC 4.3) · analysis
- PASG — Passage Bio, Inc. (QOC 4.3) · analysis
- SFCX — SUPA Consolidated Inc. (QOC 4.3) · analysis
- PMI — Picard Medical, Inc. (QOC 4.3) · analysis
- ENVB — Enveric Biosciences, Inc. (QOC 4.3) · analysis
- NVDA — NVIDIA Corporation (QOC 10.0) · analysis
Which Medical Instruments & Supplies Screens Does RGNT Appear In?
So Is Regentis Biomaterials Ltd. (RGNT) Worth Buying in 2026?
Our valuation engine sends a clear cautionary signal on Regentis Biomaterials Ltd. at $1.81. 1/1 models flag overvaluation, median fair value sits at $1.27 (-29.6%), and the risk-reward profile appears unfavorable. Quality at 4.3/10 adds to the concern. This is a stock where patience — or avoidance — may be the optimal strategy.
These are quantitative model outputs, not investment recommendations. Regentis Biomaterials Ltd.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
What Else Do Investors Ask About RGNT Stock?
Should I buy RGNT stock right now?
Based on CirclFi's multi-model analysis, 0 of 1 models see upside for RGNT at $1.81. No active models currently project upside, suggesting the market price may already reflect or exceed fair value. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in Regentis Biomaterials Ltd.?
Key risks include: a below-average Quality Score of 4.3/10, indicating fundamental weakness; limited model coverage (1/13 active), reducing analytical confidence; general market and sector-specific risks affecting Medical Instruments & Supplies companies. Always diversify and consult a financial advisor.
How does RGNT compare to its competitors?
Among Medical Instruments & Supplies peers, RGNT holds a Quality Score of 4.3/10. Comparable companies include YBGJ (QOC 4.5), UEEC (QOC 4.1), DXR (QOC 4.8). The relative ranking helps investors identify whether RGNT offers better fundamental quality than alternatives in the same sector.
Is RGNT a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. RGNT's Quality Score of 4.3/10 raises concerns about long-term viability without significant operational improvements. Check our full data page for all 13 model estimates.
What price should I buy RGNT at?
CirclFi does not provide target buy prices or price alerts. However, our 1 active models produce fair value estimates ranging from $1.27 to $1.27. At $1.81, the stock trades above all model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for RGNT.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad